Biomarin Pharmaceutical (BMRN) Total Debt Growth (1y) (2012 - 2022)
Biomarin Pharmaceutical (BMRN) Total Debt Growth (1y) (2012 - 2022) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
5.94% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
- |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
- |
| Date | Value |
|---|
| Sep 30, 2022 |
-41.26% |
| Jun 30, 2022 |
-6.98% |
| Mar 31, 2022 |
107.79% |
| Sep 30, 2021 |
-87.13% |
| Jun 30, 2021 |
-91.30% |
| Mar 31, 2021 |
-91.58% |
| Sep 30, 2020 |
3,642.90% |
| Jun 30, 2020 |
3,628.59% |
| Mar 31, 2020 |
315.13% |
| Sep 30, 2019 |
-88.40% |
| Jun 30, 2019 |
-97.32% |
| Mar 31, 2019 |
-75.87% |
| Jun 30, 2018 |
571.14% |
| Mar 31, 2018 |
707.10% |
| Dec 31, 2017 |
15.80% |
| Jun 30, 2017 |
15.21% |
| Mar 31, 2017 |
-53.55% |
| Dec 31, 2016 |
106.10% |
| Sep 30, 2016 |
-76.18% |
| Jun 30, 2016 |
-47.67% |
